Raymond T Chung, GRJ 825, GI Unit, Massachusetts General Hospital, Boston, MA 02114, USA,
Tel.: 617-724-7562; fax: 617-726-5895;
e-mail: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Abstract: Background: Histological recurrence of the hepatitis C virus (HCV) occurs in the majority of persons transplanted for cirrhosis as a result of HCV. Herein we analyze our experience with the use of both conventional and pegylated (PEG) interferon (IFN) in combination with ribavirin (RBV) in liver transplant recipients with recurrent HCV.

Methods: Patients transplanted between 1992 and 2001 with post-orthotopic liver transplantation (OLT) histological recurrence of HCV, and who were treated with at least 6 months of IFN or PEG-IFN in combination with RBV were included in this analysis. A retrospective chart review was performed.

Results: A total of 31 patients were included. Fifteen were treated with IFN/RBV and 16 with PEG-IFN/RBV. Of these 16, 11 had been begun on IFN/RBV and were changed to PEG-IFN/RBV because of persistent viremia. Three patients (20%) in the IFN/RBV group and six patients (37.5%) in the PEG-IFN/RBV group experienced a virologic response (VR) on therapy. Of the six patients experiencing VR in the PEG-IFN/RBV group, three (50%) were IFN/RBV non-responders. There were two sustained VRs (SVR). The 65.6% of all patients experienced a biochemical response (BR) on therapy. Seven deaths were observed. Dose modifications of IFN or PEG-IFN (87.1%) and RBV (80.6%) and the requirement for hematopoietic growth factors were frequent.

Conclusions: Treatment of recurrent HCV infection with combination of IFN or PEG-IFN and RBV produced an on-therapy VR in 29% and BR in 65% of patients. Hematologic toxicity and dose modifications were frequent. Our experience with antiviral therapy for HCV post-OLT remains disappointing but PEG-IFN + RBV appears to produce VR in a sizable portion of IFN + RBV non-responders.

References

1 Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001: 1: 197.
10.1034/j.1600-6143.2001.001003197.x
CAS PubMed Web of Science® Google Scholar
2 Gopal DV, Rabkin JM, Berk BS et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transplant 2001: 7: 181.
10.1053/jlts.2001.22447
CAS PubMed Web of Science® Google Scholar
3 Sheiner P. Hepatitis C after liver transplantation. Semin Liver Dis 2001: 20: 201.
10.1055/s-2000-9942
CAS Web of Science® Google Scholar
4 Wright TL, Combs C, Kim M. Interferon-alpha therapy for hepatitis C after liver transplantation. Hepatology 1994: 20: 773.
10.1002/hep.1840200402
PubMed Web of Science® Google Scholar
5 Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver patients. Transplant Proc 1995: 27: 1222.
PubMed Web of Science® Google Scholar
6 Menon KV, Poterucha JJ, El-Amin OM et al. Treatment of post-transplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transplant 2002: 8: 623.
10.1053/jlts.2002.33968
PubMed Web of Science® Google Scholar
7 Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997: 26: 500.
10.1002/hep.510260236
CAS PubMed Web of Science® Google Scholar
8 De Vera ME, Smallwood GA, Rosado K et al. Interferon- and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001: 71: 678.
10.1097/00007890-200103150-00019
CAS PubMed Web of Science® Google Scholar
9 Mazzaferro V, Regalia E, Pulvirenti A. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997: 29: 519.
10.1016/S0041-1345(96)00248-5
CAS PubMed Web of Science® Google Scholar
10 Gotz G, Schon MR, Haefker A et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998: 30: 2104.
10.1016/S0041-1345(98)00554-5
CAS PubMed Web of Science® Google Scholar
11 Hakil AO, McGuire B, Crippon J et al. A pilot study of interferon alfa and riabvirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002: 36: 1253.
10.1053/jhep.2002.36162
CAS PubMed Web of Science® Google Scholar
12 Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplant 2002: 8: 1000.
10.1053/jlts.2002.34968
PubMed Web of Science® Google Scholar
13 Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002: 347: 975.
10.1056/NEJMoa020047
CAS PubMed Web of Science® Google Scholar
14 Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001: 358: 958.
10.1016/S0140-6736(01)06102-5
CAS PubMed Web of Science® Google Scholar
15 Ishak K, Baptista A, Bianchi L, Callea F et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995: 22: 696.
10.1016/0168-8278(95)80226-6
CAS PubMed Web of Science® Google Scholar
16 Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001: 72: 1066.
10.1097/00007890-200109270-00015
CAS PubMed Web of Science® Google Scholar
17 Didier S, Bizollon T, Cyrille F et al. Interferon-a 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003: 124: 642.
10.1053/gast.2003.50095
CAS PubMed Web of Science® Google Scholar
18 Sheiner PA, Schwartz M, Mor E et al. Severe or multiple rejection episodes lead to increased early recurrence of hepatitis C following liver transplantation. Hepatology 1995: 21: 30.
10.1002/hep.1840210107
PubMed Web of Science® Google Scholar
19 Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999: 13: 539.
10.1097/00002030-199904010-00002
CAS PubMed Web of Science® Google Scholar
20 Chung R, Andersen J, Alston M et al. A randomized, controlled trial of pegylated interferon–2a with ribavirin vs interferon-α-2a with ribavirin for the treatment of chronic HCV in HIV con-infection: ACTG A5071. Seattle, WA: 9th Conference on Retroviruses and Opportunistic Infections, 2002 (Abstract LB-15).
Google Scholar
21 Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002: 36: 202.
10.1053/jhep.2002.33993
CAS PubMed Web of Science® Google Scholar
22 Sheiner PA, Boros P, Klion FM et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998: 28: 831.
10.1002/hep.510280334
CAS PubMed Web of Science® Google Scholar
23 Reddy R, Fried M, Dickson R et al. Interferon alfa-2b and ribavirin vs. placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease results of a multicenter, randomized trial. Gastroenterology 2002: 122: A632.
Web of Science® Google Scholar
24 Mazzaferro V, Tagger A, Schiavo M et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001: 33: 1355.
10.1016/S0041-1345(00)02508-2
CAS PubMed Web of Science® Google Scholar
25 Everson GT, Trotter JF, Kugelmas M. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating-dose regimen). Hepatology 2002: 36: 297A.
Web of Science® Google Scholar
26 Ringe B, Braun F, Schutz E et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001: 71: 495.
10.1097/00007890-200102270-00005
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume18, Issue2

April 2004

Pages 166-173

Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C

Abstract

References

Citing Literature

References

Related

Information